Life Science Investing Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
Life Science Investing Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
Life Science Investing Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
Life Science Investing Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
Life Science Investing Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
Life Science Investing Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
Life Science Investing Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
